Clin2
NCT07656727Possibly a fitRecruiting

A study of BGE-102 for obesity and heart risk

Obesity and Cardiovascular Risk

Part of Hormones & metabolism clinical trials.

This trial tests an experimental drug called BGE-102 in people with obesity and signs of inflammation. It aims to see if the drug can help reduce body weight and improve heart health. Participants must be willing to keep a stable diet and exercise routine.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
160 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are an adult with a body mass index (BMI) between 32 and 42 kg/m²
  • You have elevated levels of hsCRP, a blood test marker for inflammation
  • You have at least one heart risk factor or sign of metabolic syndrome (like high blood pressure, high cholesterol, or prediabetes)
  • You are not taking weight-loss medications or programs, and have not gained or lost more than 5% of your body weight recently
  • You do not have type 1 diabetes, uncontrolled type 2 diabetes, or uncontrolled high blood pressure or high cholesterol
  • You are not pregnant or nursing

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06752018Recruiting
Inflammation, heart disease, and diabetes study

This study looks at how inflammation affects heart disease and diabetes. It may help find new ways to prevent or treat these conditions.

Aarhus
NCT07793019Not yet recruiting· Phase 1
Weight loss and safety study in overweight adults

This trial tests an experimental medication that may help with weight loss. It aims to see how safe the drug is and how the body responds, possibly leading to a new treatment option for obesity.

Beijing, Beijing Municipality
NCT07224399Recruiting· Phase 1
Testing a new injection for weight loss in obesity

This trial tests a new injection (BGM1812) for weight loss in people who are overweight or obese. The injection is given under the skin, and the study will see how it works in your body and how safe it is.

Baltimore, Maryland
NCT07754474Not yet recruiting· Phase 1
Testing a new medicine for overweight or obesity

This study tests a new drug called BI 3034701 to see how well people tolerate different doses. It may help with weight loss and related health issues.

Mannheim
NCT06911203Recruiting· Phase 2
Study of BGM0504 for people with obesity

This trial tests a new medicine called BGM0504 to help people with obesity lose weight. It may be an option if diet and exercise have not been enough and you qualify for a treatment study.

Beijing, Beijing Municipality
NCT07324850Not yet recruiting· Phase 1
Study of SGB-7342 for people with obesity or overweight

This trial tests an investigational drug called SGB-7342 to see if it helps with weight loss in people who are overweight or have obesity. It might be an option if you have a stable weight and haven't used certain weight-loss medications recently.

Hear when a new Obesity and Cardiovascular Risk trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.